Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl E Ruby

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Veterinary Sciences|May 26, 2023
Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary OncologyJeilene N Hambly, Carl E Ruby, Dan V Mourich, et al.
Veterinary and Comparative Oncology|January 15, 2021
Fasting reduces the incidence of vincristine-associated adverse events in dogsMargaret E Duckett, Kaitlin M Curran, Haley J Leeper, et al.
Breast Cancer Research and Treatment|February 26, 2016
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirinSanja B Turturro, Matthew S Najor, Carl E Ruby, et al.
Cancer Research|July 3, 2008
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumorMichael J Gough, Carl E Ruby, William L Redmond, et al.
Cancer Immunology, Immunotherapy : CII|April 1, 2014
Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during agingMichelle Farazi, Justine Nguyen, Josef Goldufsky, et al.
Journal of Medical Microbiology|January 29, 2015
Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell linesJoe Goldufsky, Stephen Wood, Behnam Hajihossainlou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
IL-18 bridges innate and adaptive immunity through IFN-gamma and the CD134 pathwayJoseph R Maxwell, Rajwardhan Yadav, Robert J Rossi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 30, 2009
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is rightCarl E Ruby, Melissa A Yates, Daniel Hirschhorn-Cymerman, et al.
Oncolytic Virotherapy|August 12, 2016
Oncolytic virus therapy for cancerJoe Goldufsky, Shanthi Sivendran, Sara Harcharik, et al.
Frontiers in Chemistry|March 10, 2022
Creating a Selective Nanobody Against 3-Nitrotyrosine Containing ProteinsElise M Van Fossen, Sonia Grutzius, Carl E Ruby, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Veterinary Sciences|May 26, 2023
Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary OncologyJeilene N Hambly, Carl E Ruby, Dan V Mourich, et al.
Veterinary and Comparative Oncology|January 15, 2021
Fasting reduces the incidence of vincristine-associated adverse events in dogsMargaret E Duckett, Kaitlin M Curran, Haley J Leeper, et al.
Breast Cancer Research and Treatment|February 26, 2016
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirinSanja B Turturro, Matthew S Najor, Carl E Ruby, et al.
Cancer Research|July 3, 2008
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumorMichael J Gough, Carl E Ruby, William L Redmond, et al.
Cancer Immunology, Immunotherapy : CII|April 1, 2014
Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during agingMichelle Farazi, Justine Nguyen, Josef Goldufsky, et al.
Journal of Medical Microbiology|January 29, 2015
Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell linesJoe Goldufsky, Stephen Wood, Behnam Hajihossainlou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
IL-18 bridges innate and adaptive immunity through IFN-gamma and the CD134 pathwayJoseph R Maxwell, Rajwardhan Yadav, Robert J Rossi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 30, 2009
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is rightCarl E Ruby, Melissa A Yates, Daniel Hirschhorn-Cymerman, et al.
Oncolytic Virotherapy|August 12, 2016
Oncolytic virus therapy for cancerJoe Goldufsky, Shanthi Sivendran, Sara Harcharik, et al.
Frontiers in Chemistry|March 10, 2022
Creating a Selective Nanobody Against 3-Nitrotyrosine Containing ProteinsElise M Van Fossen, Sonia Grutzius, Carl E Ruby, et al.
Pageof 3